Task specificity of cross-tolerance between Δ9- tetrahydrocannabinol and anandamide analogs in mice

European Journal of Pharmacology

Volumn 510, Issue 1-2, 2005, Pages 59-68

  Wiley, Jenny L ^a   Smith, Forrest L ^a   Razdan, Raj K ^b   Dewey, William L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b ORGANIX INC   (United States)

Author keywords

Anandamide; Cannabinoid; Cross tolerance; Methanandamide; Tetrahydrocannabinol; Tolerance

Indexed keywords

(20 CYANO 16,16 DIMETHYLDOCOSA 5,8,11,14 TETRAENOYL) 1' HYDROXY 2' PROPYLAMINE; 2 METHYLANANDAMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; DRONABINOL; ENDOCANNABINOID; O 1812; O 680; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG CROSS TOLERANCE; DRUG EFFECT; DRUG SENSITIVITY; DRUG SPECIFICITY; EXPERIMENTAL TEST; HYPOTHERMIA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; TAIL FLICK TEST; TASK PERFORMANCE;

EID: 14644403611     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.01.006     Document Type: Article

References (34)

1. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain Pharmacol. Biochem. Behav. 46 1993 575 579
2. I.B. Adams, W. Ryan, M. Singer, R.K. Razdan, D.R. Compton, and B.R. Martin Pharmacological and behavioral evaluation of alkylated anandamide analogs Life Sci. 56 1995 2041 2048
3. I.B. Adams, W. Ryan, M. Singer, B.F. Thomas, D.R. Compton, R.K. Razdan, and B.R. Martin Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs J. Pharmacol. Exp. Ther. 273 1995 1172 1181
4. I.B. Adams, D.R. Compton, and B.R. Martin Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain J. Pharmacol. Exp. Ther. 284 1998 1209 1217
5. 9-tetrahydrocannabinol in mice Drug Alcohol Depend. 60 2000 113 119
6. C.E. Bass, G. Griffin, M. Grier, A. Mahadevan, R.K. Razdan, and B.R. Martin SR141716A-induced stimulation of locomotor activity. A structure-activity relationship study Pharmacol. Biochem. Behav. 74 2002 31 40
7. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain J. Neurochem. 73 1999 2447 2459
8. D.R. Compton, W.L. Dewey, and B.R. Martin Cannabis dependence and tolerance production Adv. Alcohol Subst. Abuse 9 1990 129 147
9. D.R. Compton, K.C. Rice, B.R. De Costa, R.K. Razdan, L.S. Melvin, M.R. Johnson, and B.R. Martin Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities J. Pharmacol. Exp. Ther. 265 1993 218 226
10. 9-tetrahydrocannabinol-induced responses and apparent agonist activity J. Pharmacol. Exp. Ther. 277 1996 586 594
11. B. Costa, G. Giagnoni, and M. Colleoni Precipitated and spontaneous withdrawal in rats tolerant to anandamide Psychopharmacology 149 2000 121 128
12. W.A. Devane, L. Hanuš, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
13. 9-tetrahydrocannabinol-tolerant rats J. Neurochem. 74 2000 1627 1635
14. 2 receptor-mediated actions of anandamide in mouse brain J. Neurochem. 75 2000 2434 2444
15. 1 vanilloid receptor "hybrid" ligands Biochem. Biophys. Res. Commun. 281 2001 444 451
16. 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212 J. Pharmacol. Exp. Ther. 271 1994 1383 1390
17. 9-tetrahydrocannabinol Brain Res. 697 1995 83 90
18. 9-THC and anandamide Brain Res. 857 2000 337 342
19. Z. Járai, J.A. Wagner, K. Varga, K.D. Lake, D.R. Compton, B.R. Martin, A.M. Zimmer, T.I. Bonner, N.E. Buckley, E. Mezey, R.K. Razdan, A. Zimmer, and G. Kunos Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors Proc. Natl. Acad. Sci. 96 1999 14136 14141
20. 9- tetrahydrocannabinol dosing Eur. J. Pharmacol. 398 2000 251 258
21. B.R. Martin, D.R. Compton, B.F. Thomas, W.R. Prescott, P.J. Little, R.K. Razdan, M.R. Johnson, L.S. Melvin, R. Mechoulam, and S.J. Ward Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs Pharmacol. Biochem. Behav. 40 1991 471 478
22. National Research Council Guide for the care and use of laboratory animals 1996 National Academy Press Washington, DC
23. R.G. Pertwee, L.A. Stevenson, and G. Griffin Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide Br. J. Pharmacol. 110 1993 1483 1490
24. 9-tetrahydrocannabinol Synapse 30 1998 298 308
25. W.J. Ryan, W.K. Banner, J.L. Wiley, B.R. Martin, and R.K. Razdan Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain J. Med. Chem. 40 1997 3617 3625
26. M.C. Sañudo-Peña, J. Romero, G.E. Seale, J.J. Fernandez-Ruiz, and J.M. Walker Activational role of cannabinoids on movement Eur. J. Pharmacol. 391 2000 269 274
27. H.H. Seltzman, D.N. Fleming, B.F. Thomas, A.F. Gilliam, D.S. McCallion, R.G. Pertwee, D.R. Compton, and B.R. Martin Synthesis and pharmacological comparison of dimethylheptyl and pentyl anandamide analogs J. Med. Chem. 40 1997 3626 3634
28. P.B. Smith, D.R. Compton, S.P. Welch, R.K. Razdan, R. Mechoulam, and B.R. Martin The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice J. Pharmacol. Exp. Ther. 270 1994 219 227
29. 9-THC-induced interactions with dynorphinergic systems Drug Alcohol Depend. 45 1997 39 45
30. S.P. Welch, and M. Eads Synergistic interactions of endogenous opioids and cannabinoid systems Brain Res. 848 1999 183 190
31. 9-THC-induced antinociception J. Pharmacol. Exp. Ther. 273 1995 1235 1244
32. S.P. Welch, J.W. Huffman, and J. Lowe Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A J. Pharmacol. Exp. Ther. 286 1998 1301 1308
33. J.L. Wiley, and B.R. Martin Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes Chem. Phys. Lipids 121 2002 57 63
34. 9-tetrahydrocannabinol Behav. Pharmacol. 4 1993 581 585